Syndax Pharmaceuticals receives Galien Foundation award for Revuforj
1 report, 1 independent
Updated 00:00
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Syndax Pharmaceuticals was recognized by The Galien Foundation as the Best Product for Rare/Orphan Diseases of 2026. The award honors Revuforj, a menin inhibitor that is approved for adults and children one year and older with relapsed or refractory acute leukemia. Revuforj received FDA approval in November 2024 for KMT2A translocation and expanded that approval in October 2025.
From manilatimes.net
Why it matters
The recognition validates the scientific innovation behind Revuforj. The drug is noted as the first and only menin inhibitor approved for multiple types of relapsed or refractory acute leukemia.
From manilatimes.net
Who's involved
- Syndax PharmaceuticalsCommercial-stage biopharmaceutical company that received the award for its cancer therapy.
- GalenThe organization that honored Syndax Pharmaceuticals with the award.
- FDAThe regulatory body that approved Revuforj for acute leukemia treatments.